tiprankstipranks
Advertisement
Advertisement

CADL Stock Latest News

Candel Therapeutics Stockholders Approve Directors and Auditor
Company AnnouncementsCandel Therapeutics Stockholders Approve Directors and Auditor
6d ago
8K
CADL
Candel Therapeutics Updates Employment Agreement with Chief Financial Officer
PremiumCompany Announcements
Candel Therapeutics Updates Employment Agreement with Chief Financial Officer
14d ago
8K
CADL
Analyst Reiterates Buy Rating on Strengthened Phase 3 Data for Aglatimagene Besadenovec, Maintains $23 Price Target
PremiumRatings
Analyst Reiterates Buy Rating on Strengthened Phase 3 Data for Aglatimagene Besadenovec, Maintains $23 Price Target
28d ago
CADL
Candel Therapeutics publishes pivotal Phase 3 data for Aglatimagene
PremiumThe Fly
Candel Therapeutics publishes pivotal Phase 3 data for Aglatimagene
28d ago
CADL
Candel Therapeutics price target raised to $9 from $7 at BofA
PremiumThe Fly
Candel Therapeutics price target raised to $9 from $7 at BofA
1M ago
CADL
Candel Therapeutics Highlights Phase 3 Prostate Cancer Data
PremiumCompany AnnouncementsCandel Therapeutics Highlights Phase 3 Prostate Cancer Data
2M ago
8K
CADL
Candel Therapeutics initiated with an Overweight at Cantor Fitzgerald
Premium
The Fly
Candel Therapeutics initiated with an Overweight at Cantor Fitzgerald
2M ago
CADL
Candel Therapeutics price target raised to $26 from $22 at Citi
Premium
The Fly
Candel Therapeutics price target raised to $26 from $22 at Citi
3M ago
CADL
CAN-2409’s Emerging Survival Benefit and Biomarker-Driven Immunotherapy Platform Support Buy Rating and $23 Target
PremiumRatings
CAN-2409’s Emerging Survival Benefit and Biomarker-Driven Immunotherapy Platform Support Buy Rating and $23 Target
3M ago
CADL
Candel Therapeutics’ aglatimagene shows extended long-term survival in NSCLC
PremiumThe Fly
Candel Therapeutics’ aglatimagene shows extended long-term survival in NSCLC
3M ago
CADL
Candel Therapeutics: Strengthened Balance Sheet and Late‑Stage Pipeline Catalysts Support High‑Risk Buy Rating Despite Dilution
PremiumRatings
Candel Therapeutics: Strengthened Balance Sheet and Late‑Stage Pipeline Catalysts Support High‑Risk Buy Rating Despite Dilution
4M ago
CADL
Candel Therapeutics price target lowered to $22 from $24 at Citi
PremiumThe Fly
Candel Therapeutics price target lowered to $22 from $24 at Citi
4M ago
CADL
Restrictive RTW Purchase Agreement Covenants Threaten Candel Therapeutics’ Financial Flexibility and Increase Default Risk
PremiumCompany AnnouncementsRestrictive RTW Purchase Agreement Covenants Threaten Candel Therapeutics’ Financial Flexibility and Increase Default Risk
4M ago
CADL
Candel Therapeutics: Advancing CAN-2409 Toward a 2026 BLA on Strengthening Prostate Cancer Data and Solid Cash Runway
Premium
Ratings
Candel Therapeutics: Advancing CAN-2409 Toward a 2026 BLA on Strengthening Prostate Cancer Data and Solid Cash Runway
4M ago
CADL
Candel Therapeutics: Advancing CAN-2409 Toward BLA With Platform-Like Oncology Potential and Diversified Pipeline Upside
Premium
Ratings
Candel Therapeutics: Advancing CAN-2409 Toward BLA With Platform-Like Oncology Potential and Diversified Pipeline Upside
4M ago
CADL
Candel Therapeutics reports Q4 EPS (54c) vs. (40c) last year
PremiumThe Fly
Candel Therapeutics reports Q4 EPS (54c) vs. (40c) last year
4M ago
CADL
Candel Therapeutics sees cash runway into 1Q28
PremiumThe Fly
Candel Therapeutics sees cash runway into 1Q28
4M ago
CADL
Candel Therapeutics Announces Equity Offering to Fund CAN-2409
PremiumCompany Announcements
Candel Therapeutics Announces Equity Offering to Fund CAN-2409
4M ago
8K
CADL
Candel Therapeutics 18.3M share Spot Secondary priced at $5.45
PremiumThe Fly
Candel Therapeutics 18.3M share Spot Secondary priced at $5.45
4M ago
CADL
Candel Therapeutics 18.3M share Spot Secondary priced at $5.45
PremiumThe FlyCandel Therapeutics 18.3M share Spot Secondary priced at $5.45
4M ago
CADL
Candel Therapeutics announces $100M royalty funding agreement
Premium
The Fly
Candel Therapeutics announces $100M royalty funding agreement
4M ago
CADL
Candel Therapeutics Secures $100M Royalty Funding for CAN-2409
Premium
Company Announcements
Candel Therapeutics Secures $100M Royalty Funding for CAN-2409
4M ago
8K
CADL

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >